Neoadjuvant Treatment in Pancreatic Cancer

Atsushi Oba; Atsushi Oba; Felix Ho; Quoc Riccardo Bao; Quoc Riccardo Bao; Mohammed H. Al-Musawi; Richard D. Schulick; Marco Del Chiaro

doi:10.3389/fonc.2020.00245

Frontiers in Oncology (Feb 2020)

Neoadjuvant Treatment in Pancreatic Cancer

Atsushi Oba,
Atsushi Oba,
Felix Ho,
Quoc Riccardo Bao,
Quoc Riccardo Bao,
Mohammed H. Al-Musawi,
Richard D. Schulick,
Marco Del Chiaro

Affiliations

Atsushi Oba: Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States
Atsushi Oba: Department of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Felix Ho: Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States
Quoc Riccardo Bao: Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States
Quoc Riccardo Bao: Department of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy
Mohammed H. Al-Musawi: Clinical Trials Office, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States
Richard D. Schulick: Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States
Marco Del Chiaro: Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Denver, CO, United States

DOI: https://doi.org/10.3389/fonc.2020.00245
Journal volume & issue: Vol. 10

Abstract

Read online

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide agree that the treatment of PDAC demands a multidisciplinary approach. Neoadjuvant treatment (NAT) plays a major role in the treatment of PDAC since only about 20% of patients are considered resectable at the time of diagnosis. Moreover, increasing data demonstrating the benefits of NAT for borderline resectable/locally advanced PDAC are driving a shift from up-front surgery to NAT in the multidisciplinary treatment of even resectable PDAC. Our understanding of the role of NAT in PDAC has evolved from tumor shrinkage to controlling potential micrometastases and selecting patients who may benefit from radical resection. The present review gives an overview on the current literature of NAT concepts for BR/LA PDAC and resectable PDAC.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords